Anticancer Potential of Ripened Jackfruit Flour Compounds Compared to Tamoxifen: A Docking Analysis

Even after tremendous development in the field of breast cancer treatment, it remains a worldwide menace. Scientists in various parts of the world are trying hard to contain the threat. Major sources of breast cancer treatment like Tamoxifen, a cornerstone therapy, are associated with adverse impacts. This study discovered some anti-cancer components from the ripened jackfruit flour and compared their binding affinities to a crucial breast cancer target protein with those of Tamoxifen. Ripened jackfruit flour was extracted in methanol and subjected to LC-MS analysis, showing a complex mixture, with mass spectral signals observed at m/z 494.2329, 353.276, and 169.0895. Putative compounds corresponding to these ions were selected for molecular docking studies. A glide docking panel within Maestro 11.9 (Schrödinger Suite) was used to conduct molecular docking for these possible compounds. Human Estrogen Receptor Alpha Ligand-Binding Domain (ERα LBD), with the structure of the GW5638-ERα LBD complex (PDB ID: 1R5K), was the protein used for docking. Of these, some tentative compounds accomplished a Glide score of -5 (kcal/mol) or better while interacting with the Human Estrogen Receptor Alpha. Among these, the compound tentatively identified as 1,7-bis(4-hydroxyphenyl)-5-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptan-3-one exhibited a remarkable binding energy of -10.005, beating Tamoxifen's binding energy of -9.856 in docking experiments. Based on docking scores, the current study suggests that among the possible compounds identified in ripened jackfruit flour, the diarylheptanoid derivative, proven to have a significant role in interacting with the ERα protein and needs further investigation.

View article page

Download PDF